Catalog No.
DHG52099
Description
Anetumab ravtansine is an ADC consisting of a Mesothelin-directed antibody and DM4 used for the study of several solid tumors.
Species reactivity
Human
Clonality
Monoclonal
Target
Mesothelin
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SEC.
Purification
Purified by Ion Exchange Chromatography.
Applications
Research Grade Biosimilar
Form
Liquid
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MF-T-SPDB-DM4
Clone ID
Anetumab ravtansine
Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin., PMID:40240561
Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer., PMID:40051118
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)., PMID:39836408
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma., PMID:39197359
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study., PMID:36564099
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial., PMID:35358455
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine., PMID:34876673
In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab., PMID:34014767
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia., PMID:33938941
Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer., PMID:33356644
Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells., PMID:32815024
Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies., PMID:32547645
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors., PMID:32213105
Antibody-drug conjugates in gynecologic malignancies., PMID:30929824
Targeting mesothelin in ovarian cancer., PMID:30546824
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models., PMID:30344925
Mesothelin as a target for cervical cancer therapy., PMID:30324544
[Systemic Treatment of Malignant Pleural Mesothelioma]., PMID:29361614
Antibodies to watch in 2017., PMID:27960628
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?, PMID:27863199
Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors., PMID:27853672
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect., PMID:24714131
For research use only. Not for human or drug use.
